On the heels of disclosing last week that the company had adopted a stockholder rights plan – otherwise known as a “poison pill” for protection against hostile takeovers – Durham’s Heat Biologics (Nasdaq: HTBX) and its subsidiary Pelican Therapeutics have recruited some new scientific expertise.
Heat disclosed in a filing with the SEC on Monday that medical oncologist Dr. Anthony Tolcher has joined the respective scientific advisory boards of both Heat and Pelican.